Q-omics provides the consensus-scored MIR4287 profile across patient tissues and cancer cell-line models. MIR4287 expression is associated with patient survival in 5 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MIR4287 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR4287 RNA expression shows 5,508 significant gene co-expression associations, with the highest sampling consensus in LUSC. Together, these results highlight STAD, BRCA, and LUSC as cancer lineages where MIR4287 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4287 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4287 survival associations across molecular data types. MIR4287 RNA expression shows survival associations in the most cancer types (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4287 RNA expression–survival associations across cancer types. High MIR4287 expression shows unfavorable associations in STAD, THCA, UCEC and LGG, but favorable associations in ESCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MIR4287 RNA expression.
This table summarizes MIR4287 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4287. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4287 shows lower tumor expression in BRCA. The BRCA box plot shows higher MIR4287 RNA expression in normal versus tumor tissue (log2 FC = −0.082, t-test p = .005).
This table shows molecular features associated with MIR4287 in patient tissues and cancer cell lines. In patient samples, MIR4287 shows the broadest associations at the RNA and protein expression levels, with LUSC recurring as the lineage with the largest associated feature set.
